Analyst Activity – Sanford C. Bernstein Initiates Coverage On Ultragenyx Pharmaceutical (NASDAQ:RARE) With a Market Perform

ME Staff
-
0

Analyst Ratings For Ultragenyx Pharmaceutical (NASDAQ:RARE)

Today, Sanford C. Bernstein initiated coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Market Perform.

There are 1 sell rating, 6 hold ratings, 8 buy ratings on the stock.

The current consensus rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) is Hold (Score: 2.47) with a consensus target price of $87.00 per share, a potential 22.83% upside.

Some recent analyst ratings include

  • 7/27/2017-Sanford C. Bernstein initiated coverage with a Market Perform rating.
  • 7/14/2017-Jefferies Group LLC Reiterated Rating of Hold.
  • 6/30/2017-Stifel Nicolaus Reiterated Rating of Buy.
  • 6/29/2017-Cowen and Company Reiterated Rating of Outperform.
  • 5/8/2017-Canaccord Genuity Reiterated Rating of Buy.
  • 4/19/2017-Robert W. Baird Reiterated Rating of Outperform.

Recent Insider Trading Activity For Ultragenyx Pharmaceutical (NASDAQ:RARE)
Ultragenyx Pharmaceutical (NASDAQ:RARE) has insider ownership of 9.20% and institutional ownership of 95.32%.

  • On 5/26/2017 Theodore Alan Huizenga, VP, sold 480 with an average share price of $57.46 per share and the total transaction amounting to $27,580.80. View SEC Filing
  • On 3/9/2017 Theodore Alan Huizenga, Insider, sold 2,500 with an average share price of $86.34 per share and the total transaction amounting to $215,850.00. View SEC Filing
  • On 3/2/2017 Shalini Sharp, CFO, sold 12,000 with an average share price of $90.10 per share and the total transaction amounting to $1,081,200.00. View SEC Filing
  • On 2/27/2017 Shalini Sharp, CFO, sold 12,000 with an average share price of $80.14 per share and the total transaction amounting to $961,680.00. View SEC Filing
  • On 12/5/2016 William Aliski, Director, sold 6,000 with an average share price of $78.19 per share and the total transaction amounting to $469,140.00. View SEC Filing
  • On 11/9/2016 Shalini Sharp, CFO, sold 24,000 with an average share price of $71.20 per share and the total transaction amounting to $1,708,800.00. View SEC Filing
  • On 10/19/2016 Shalini Sharp, CFO, sold 12,000 with an average share price of $61.40 per share and the total transaction amounting to $736,800.00. View SEC Filing

Recent Trading Activity for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Shares of Ultragenyx Pharmaceutical closed the previous trading session at 71.77 up +0.94 1.33% with 197,927 shares trading hands.